Surgery is the most common treatment for thyroid cancer. The vast majority of people diagnosed with thyroid cancer will have either part or all of their thyroid gland removed, and for many, that surgery alone is the only treatment needed. What happens after surgery depends on the size of the tumor, its specific characteristics, and whether it has spread.
Surgery: The Primary Treatment
There are two main surgical options for thyroid cancer. A lobectomy removes only the half of the thyroid containing the tumor. A total thyroidectomy removes the entire gland. For decades, nearly everyone with a thyroid cancer nodule larger than 1 cm was advised to have a total thyroidectomy. That changed in 2015 when the American Thyroid Association updated its guidelines significantly.
Under the current guidelines, people with low-risk thyroid cancer up to 4 cm in size are now eligible for a lobectomy, provided the tumor hasn’t grown beyond the thyroid, doesn’t show aggressive features under the microscope, and hasn’t visibly spread to lymph nodes. This shift matters because a lobectomy preserves some of your natural thyroid function, eliminates the risk of a specific complication called hypoparathyroidism (which affects calcium regulation), and carries a lower chance of nerve damage that can affect your voice.
A total thyroidectomy is still recommended when tumors are larger than 4 cm, when cancer has spread to lymph nodes or nearby structures, or when the cancer type is more aggressive. One practical advantage of removing the entire gland is that doctors can then track a protein called thyroglobulin in your blood. Since only thyroid tissue produces it, a rising level after total thyroidectomy is a reliable signal that cancer may have returned.
What Genetic Testing Reveals Before Surgery
Before surgery, many people have a biopsy that includes molecular testing of the thyroid nodule. The most common mutation found in papillary thyroid cancer, the most frequent type, is called BRAF V600E. Finding this mutation confirms the diagnosis of papillary thyroid cancer with near 100% certainty, which helps you and your surgeon plan the right operation in advance. While BRAF has been linked to more aggressive features like spread to lymph nodes, most tumors with this mutation still don’t behave aggressively. A positive BRAF result is a clear indication for surgery, but it doesn’t automatically dictate whether you need a lobectomy or a total thyroidectomy.
Recovery After Thyroid Surgery
Most people go home within a day or two of thyroid surgery. The most common complication after a total thyroidectomy is low calcium levels, which occurs in 25% to 40% of patients in the short term. This happens because the parathyroid glands, four tiny structures that sit right behind the thyroid and control calcium in your blood, can be temporarily stunned during surgery. Symptoms include tingling in the fingers, lips, or around the mouth, and muscle cramps. In most cases this resolves within six months. About 5% to 10% of patients develop permanently low calcium levels and need to take calcium and vitamin D supplements for life.
A lobectomy avoids this risk entirely, which is one reason the shift toward less extensive surgery for low-risk cancers has been welcomed by patients and surgeons alike.
Radioactive Iodine After Surgery
Some people need a second treatment after a total thyroidectomy: radioactive iodine. Thyroid cells are uniquely good at absorbing iodine, so swallowing a radioactive form of it delivers targeted radiation to any remaining thyroid tissue or microscopic cancer cells that surgery couldn’t remove. This treatment is considered safe and effective for destroying leftover tissue in the thyroid bed.
Not everyone needs it. The clearest benefit is for higher-risk patients: those with tumors that grew beyond the thyroid capsule, cancer in lymph nodes, larger tumors over 4 cm, or aggressive cell types. For low-risk patients with small, contained cancers, the benefit is less certain, and many are spared this step entirely. When it is used in low-risk cases, lower doses tend to work well, with ablation success rates above 80% at six months. Higher-risk cases typically receive larger doses.
Before radioactive iodine treatment, you’ll need to have high levels of thyroid-stimulating hormone (TSH) in your blood, either by stopping thyroid hormone pills for a few weeks or by receiving an injection that raises TSH artificially. The treatment itself is straightforward: you swallow a capsule and then limit close contact with others for a few days while the radioactivity clears your body.
Thyroid Hormone Therapy
After a total thyroidectomy, you’ll take a daily thyroid hormone pill for the rest of your life. This serves two purposes: it replaces the hormones your body can no longer make, and it keeps TSH levels low enough to discourage any remaining thyroid cancer cells from growing, since TSH acts as a growth signal for these cells.
How aggressively your TSH needs to be suppressed depends on your risk level. For low-risk patients whose follow-up blood work shows no sign of remaining cancer, guidelines generally recommend keeping TSH in a low-normal range, roughly 0.5 to 2.0 mU/L. This is close enough to normal that most people feel well and avoid side effects of excessive suppression, like bone thinning or heart rhythm issues. Patients with higher-risk features or evidence of residual disease typically need tighter suppression, with TSH kept below 0.5 mU/L.
If you had only a lobectomy, your remaining thyroid lobe often produces enough hormone on its own, and you may not need any medication at all.
Active Surveillance Instead of Surgery
For the smallest thyroid cancers, surgery isn’t always the first step. Papillary thyroid microcarcinomas, defined as tumors smaller than 1 cm, can sometimes be safely monitored with regular ultrasounds rather than immediately operated on. This approach, called active surveillance, is best suited for patients whose tiny tumors are not near critical structures, show no signs of spread, and have no worrisome features on imaging.
Age plays a role in eligibility. Patients under 40 are more likely to see tumor growth over time, making them less ideal candidates for watching and waiting. Pregnancy planning is another consideration, since hormonal changes could potentially stimulate growth. The approach also requires a medical team experienced in thyroid cancer surveillance and a patient willing to commit to ongoing monitoring. If the tumor grows or develops concerning features, surgery is performed at that point with no loss in outcomes.
Treatment for Advanced or Resistant Cases
A small percentage of thyroid cancers either spread to distant sites or stop responding to radioactive iodine. For these cases, targeted drug therapies have become the standard approach. Two drugs that block blood vessel growth and other cancer-driving pathways are the main first-line options for radioiodine-resistant thyroid cancer, with a third available as a second-line treatment if those don’t work.
Beyond these broader-acting drugs, precision therapies now exist for cancers with specific genetic changes. Tumors carrying certain gene fusions or mutations can be matched to drugs designed to block those exact molecular targets. This kind of treatment is becoming increasingly important, though it applies to a relatively small subset of patients.
Survival Rates and Long-Term Outlook
Thyroid cancer, particularly the papillary type that accounts for roughly 80% of cases, has one of the highest survival rates of any cancer. A large retrospective study of over 1,000 patients found a 20-year survival rate of 98% for those with low-risk disease. Even among patients with high-risk features, the 20-year survival was 50%, reflecting that advanced cases still carry meaningful risk but that many people live for years even with more aggressive disease.
The excellent prognosis for most thyroid cancer patients is precisely why treatment guidelines have shifted toward less aggressive approaches when appropriate. Removing only half the thyroid, skipping radioactive iodine for low-risk cases, and even choosing active surveillance for the tiniest cancers all reflect a growing understanding that for most people, thyroid cancer can be managed effectively without the full arsenal of treatments that were once routine.